OpenArc Corporate Advisory’s Kiniksa Pharmaceuticals KNSA Stock Holding History

OpenArc Corporate Advisory’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.33M	Buy	48,353 +14,491	+43%	+$642K	0.03%	229
2025 Q4	$1.4M	Buy	+33,862	New	+$1.36M	0.02%	259

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

OpenArc Corporate Advisory's KNSA Position: Q1 2026 in Review

OpenArc Corporate Advisory increased its Kiniksa Pharmaceuticals (KNSA) stake by 43% in Q1 2026, buying an estimated $642K and bringing the position to 48,353 shares worth $2.33M. The position accounts for 0.03% of the portfolio, ranked #229.

OpenArc Corporate Advisory first reported a position in KNSA in Q4 2025 and has held it in 2 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

OpenArc Corporate Advisory held 48,353 shares of Kiniksa Pharmaceuticals worth $2.33M as of Q1 2026.
OpenArc Corporate Advisory bought 14,491 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $642K.
Kiniksa Pharmaceuticals made up 0.03% of OpenArc Corporate Advisory's portfolio in Q1 2026, its #229 holding.
OpenArc Corporate Advisory first reported a position in Kiniksa Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q1 2026, filed 11 May 2026.